Patient population
| Anterolateral group (n = 151) | Anteroposterior group (n = 150) | p Value | |
|---|---|---|---|
| Male | 94 (62%) | 89 (59%) | NS |
| Age (years) | 62 (12) | 62 (11) | NS |
| Body weight (kg) | 75 (14) | 77 (15) | NS |
| Aetiology | |||
| No heart disease found | 39 (26%) | 32 (21%) | NS |
| Systemic hypertension | 41 (27%) | 40 (27%) | NS |
| Valvar heart disease | 42 (28%) | 43 (29%) | NS |
| Coronary artery disease | 14 (9%) | 18 (12%) | NS |
| Cardiomyopathy | 15 (10%) | 17 (11%) | NS |
| AF duration (days) | 84 (92) | 92 (96) | NS |
| Previous AF episodes | 75 (50%) | 75 (50%) | NS |
| Atrial diameter (mm) | 44 (6) | 45 (6) | NS |
| LVEF (%) | 52 (12) | 52 (12) | NS |
| Antiarrhythmic drug treatment | |||
| Total | 99 (66%) | 97 (65%) | NS |
| Quinidine | 2 (1%) | 3 (2%) | NS |
| Propafenone | 25 (17%) | 18 (12%) | NS |
| Flecainide | 3 (2%) | 1 (1%) | NS |
| Amiodarone | 62 (41%) | 69 (46%) | NS |
| Sotalol | 7 (5%) | 6 (4%) | NS |
Values are expressed as mean (SEM) or n (%).
AF, atrial fibrillation; LVEF, left ventricular ejection fraction.